Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme
Launched by ADVANCED MARKER DISCOVERY S.L. · Nov 16, 2024
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how people feel about different ways to screen for colorectal cancer, which is cancer of the colon or rectum. The study aims to understand what screening methods people prefer and how they feel about their experiences with these tests, specifically after taking a stool test called FOBT (Fecal Occult Blood Test). The trial will involve participants aged 50 to 69 years who are healthy and eligible for screening. They will complete two questionnaires to share their thoughts and experiences, and their responses will help improve future screening programs.
To participate, individuals need to be between 50 and 69 years old and be invited to join a screening program at a health center. They must also be willing to sign a consent form, confirming they understand what the study involves. However, individuals who have already had a colonoscopy because of a previous positive stool test, or who haven’t submitted a stool sample yet, won’t be eligible. This study is important because it aims to make colorectal cancer screening more patient-friendly by taking into account what people prefer and how they feel about the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
- • Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
- • Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
- Exclusion Criteria:
- • Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.
- • Participants with a previous colonoscopy in consequence of a FOBT positive result.
- • Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.
About Advanced Marker Discovery S.L.
Advanced Marker Discovery S.L. is a leading biotechnology company focused on the development and commercialization of innovative diagnostic solutions and therapeutic biomarkers. With a commitment to advancing precision medicine, the company leverages cutting-edge technologies and extensive research to identify and validate novel biomarkers that enhance disease detection, monitoring, and treatment efficacy. Through strategic collaborations and robust clinical trial sponsorship, Advanced Marker Discovery aims to transform patient care by providing healthcare professionals with actionable insights and tools to improve clinical outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lisbon, Portugal
Madrid, Spain
Patients applied
Trial Officials
Maria A Perez, MD
Principal Investigator
Primary Health Care Centre Mar Báltico
Ana Rita, MD
Principal Investigator
Unidade Local de Saúde de Santa Maria
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported